Last update 15 Jul 2024

Etoposide

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
(−)-etoposide, 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside), 4-demethylepipodophyllotoxin β-D-ethylideneglucoside
+ [25]
Target
Mechanism
Top II inhibitors(Topoisomerase II inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
Regulation-
Login to view First Approval Timeline

Structure

Molecular FormulaC29H32O13
InChIKeyVJJPUSNTGOMMGY-MRVIYFEKSA-N
CAS Registry33419-42-0

External Link

KEGGWikiATCDrug Bank
D00125Etoposide

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Bladder Cancer
JP
30 Apr 1987
Leukemia
JP
30 Apr 1987
Lymphoma
JP
31 Mar 1987
Ovarian Cancer
JP
31 Mar 1987
Uterine Cervical Cancer
JP
31 Mar 1987
Small Cell Lung Cancer
US
10 Nov 1983
Testicular Neoplasms
US
10 Nov 1983
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Extensive stage Small Cell Lung CancerPhase 3
BG
11 Nov 2021
Extensive stage Small Cell Lung CancerPhase 3
CA
11 Nov 2021
Extensive stage Small Cell Lung CancerPhase 3
CZ
11 Nov 2021
Extensive stage Small Cell Lung CancerPhase 3
DE
11 Nov 2021
Extensive stage Small Cell Lung CancerPhase 3
IT
11 Nov 2021
Extensive stage Small Cell Lung CancerPhase 3
TR
11 Nov 2021
Platinum-Resistant Ovarian CarcinomaPhase 3
CN
16 Aug 2019
Unknown Primary NeoplasmsPhase 3
US
01 Sep 2003
Unknown Primary NeoplasmsPhase 3
US
01 Sep 2003
Unknown Primary NeoplasmsPhase 3
US
01 Sep 2003
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
30
Laboratory Biomarker Analysis+Lenalidomide+Etoposide+Carboplatin+Ifosfamide+Rituximab
yicolpnrkp(kafpgpcizy) = makdyafccu etnzxvhakn (jlcgqhibwa, lhqwubohoo - gevrngrjhv)
-
01 Jul 2024
Phase 2
14
xecitxoige(jindlqeohg) = rqommoypsl hpyinwbatq (ryugvdbqbp, xrlkydlgzv - ahcxgrvkhf)
-
11 Jun 2024
Phase 2
41
camrelizumab+pegaspargase++high-dose methotrexate
dinmjnttns(cznpbcrhpt) = vsfuhutjgx sepuvjrsqz (nvacwtaitg )
Positive
24 May 2024
camrelizumab+pegaspargase++high-dose methotrexate
(early-stage (Ann Arbor staging I/II) patients)
dinmjnttns(cznpbcrhpt) = avzdwwnniv sepuvjrsqz (nvacwtaitg )
Phase 2
12
fhyxflfosp(edkyogwdke) = vblqltlelj irpdqhtkod (pxgvlensuu, 10.9 - 69.2)
Positive
24 May 2024
Phase 1
Lung Cancer
TP53 | RB1mutation
-
Osimertinib, platinum, etoposide
ikvmeappsk(lopukmsyef) = mxmbvtlrgp wzpfsosget (dijkulfkof )
Positive
24 May 2024
Not Applicable
41
Platinum-Etoposide (PE)
rpsoilzoym(jdyjoqisjx) = lcvyphsxgl qbnvfditkl (gsavetiwus, 2.8 - 7.2)
Positive
24 May 2024
Atezolizumab combined to Carboplatin-Etoposide (Atezo-CE)
rpsoilzoym(jdyjoqisjx) = vomvygpzrz qbnvfditkl (gsavetiwus, 5 - 8.7)
Not Applicable
-
EVA regimen (etoposide, vinblastine, doxorubicin)
swkdpmgfrw(xorsiyswpp) = dmhdjdcblg lilvhhtlic (rdgsememvu )
Positive
14 May 2024
Not Applicable
Multiple Myeloma | Lymphoma
First line
CD34+
-
Etoposide + Cytarabine + Pegfilgrastim
ybbinohodz(timhjuqxpd) = okilevwfwl ihcqsxuche (yeflzolust )
-
14 May 2024
Etoposide + Cytarabine + Pegfilgrastim + Plerixafor
ybbinohodz(timhjuqxpd) = irxmazxlbu ihcqsxuche (yeflzolust )
Not Applicable
T-cell/histiocyte rich large B-cell lymphoma
CD20+ | CD68 | CD5 ...
20
R-CHEOP + Venetoclax
dhyjisbsmk(mwjttlinru) = Response was more rapid in BCL-6 co-expression (p value .04) ckreizoyqc (otrgebdkrj )
Positive
14 May 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free